Literature DB >> 7134879

The in vivo metabolism of C3 in hepatobiliary disease associated with ulcerative colitis.

L Brinch, P Teisberg, E Schrumpf, I Akesson.   

Abstract

To study possible pathogenetic mechanisms in hepatobiliary disease associated with ulcerative colitis (UC), we performed a metabolic investigation of component C3 of the most important effector of humoral immunity, the complement system. Purified and biologically active C3 was labelled with 125I and injected together with 131I-albumin into seven patients. All had hepatobiliary disease, and total colectomy had previously been performed for severe UC in all patients. The results were compared with those for 16 normal individuals. The fractional catabolic rates (FCR) were calculated by the metabolic clearance method and by analysis of the plasma radioactivity disappearance curve. An increase in the FCR of C3 was found in the patient group, indicating that humoral immune mechanisms may be of pathogenetic importance in hepatobiliary disease associated with UC. The increased FCR was compensated for by and increased synthesis rate of the protein.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7134879     DOI: 10.3109/00365528209182243

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

Review 1.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Suppressor T-cell deficiency in primary sclerosing cholangitis. Case and family study.

Authors:  A E Kilby; E L Krawitt; R J Albertini; B F Chastenay; A John
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

Review 3.  The immunology of primary sclerosing cholangitis.

Authors:  R W Chapman
Journal:  Springer Semin Immunopathol       Date:  1990

4.  Bile duct antibodies crossreacting with blood group antigens in primary sclerosing cholangitis.

Authors:  G P Jeffrey; N R Swanson; L J Yarred; W D Reed
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

5.  Inappropriate expression of blood group antigens on biliary and colonic epithelia in primary sclerosing cholangitis.

Authors:  S Bloom; A Heryet; K Fleming; R W Chapman
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

Review 6.  Aetiology and pathophysiology of chronic liver disorders.

Authors:  J Schölmerich; A Holstege
Journal:  Drugs       Date:  1990       Impact factor: 9.546

7.  Histological and immunohistochemical study of the gall bladder lesion in primary sclerosing cholangitis.

Authors:  G P Jeffrey; W D Reed; S Carrello; K B Shilkin
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

8.  Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis.

Authors:  R W Chapman; M Cottone; W S Selby; H A Shepherd; S Sherlock; D P Jewell
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

9.  Lymphocyte subsets in primary sclerosing cholangitis.

Authors:  K D Lindor; R H Wiesner; J A Katzmann; N F LaRusso; S J Beaver
Journal:  Dig Dis Sci       Date:  1987-07       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.